Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,625.00-0.16%ETH$2,695.12-0.64%GOLD$4,192.00+0.85%OIL$89.75+0.36%
Smart Investors Daily
SID Premium
Avalo Therapeutics, Inc. logo

NASDAQ · AVTX

Avalo Therapeutics, Inc.

Healthcare · Biotechnology

$14.60

Down-$1.01 (-6.92%)

Updated Oct 6, 2026, 8:39 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
220.35M
P/E ratio
-2.73
Dividend yield
0.00%
52-week range
$12.51 – $24.27
Volume
736.84K
Avg. volume
410.27K

Price performance · AVTX

AVTX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

AVTX closed at $14.60 after 20 trading sessions, down 25.93% for the selected period.

Last close
$14.60
Period change
-25.93%
Period low
$14.60
Period high
$19.71
Daily close
View OHLC price history
AVTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$15.09$15.09$14.39$14.60736.84K
Oct 2, 2026$15.05$15.16$14.3081$14.99948.52K
Oct 1, 2026$15.24$15.57$14.78$14.95932.39K
Sep 30, 2026$15.80$15.99$15.14$15.331.43M
Sep 29, 2026$15.16$15.67$14.74$15.581.33M
Sep 28, 2026$15.47$15.47$14.97$15.08749.65K
Sep 25, 2026$15.75$15.81$15.00$15.471.43M
Sep 24, 2026$15.24$16.10$14.58$15.721.9M
Sep 23, 2026$16.40$16.49$15.13$15.301.11M
Sep 22, 2026$16.44$16.865$16.28$16.51585.53K
Sep 21, 2026$16.57$16.75$15.92$16.17542.68K
Sep 18, 2026$16.66$16.925$16.34$16.573.23M
Sep 17, 2026$17.105$17.19$16.52$16.69691.27K
Sep 16, 2026$16.17$16.695$15.87$16.581.44M
Sep 15, 2026$16.13$16.69$15.39$16.071.1M
Sep 14, 2026$16.43$16.53$16.12$16.18908.42K
Sep 11, 2026$17.42$18.135$16.02$16.122.53M
Sep 10, 2026$17.92$18.05$17.15$17.18913.75K
Sep 9, 2026$19.47$19.74$18.035$18.21725.72K
Sep 8, 2026$19.01$20.49$18.95$19.71779.7K

Latest AVTX news

The latest Smart Investors Daily articles mentioning AVTX.

Stock researchCompany · Overview

AVTX research

Overview

Company profile and research snapshot.

Company profile

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$25.00
Implied upside
—
Analysts
—
AVTX recent ratings
DateFirmRatingTarget
Aug 7, 2026GuggenheimBuy—
Aug 7, 2026HC Wainwright & Co.Buy—
Jul 6, 2026Leerink PartnersOutperform—
Jun 16, 2026BTIGBuy—
Jun 12, 2026B of A SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 101,600 shares of common stock (the “Options”)

Yahoo · Sep 23, 2026

Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress

WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced a late-breaker oral presentation and poster at the upcoming EADV Congress 2026, to be held in Vienna, Austria from September 30-October 3, 2026. EADV Congress 2026 Presentation Details: Late-Breaker Oral Presentation: Title: Efficacy and Safety of A

Yahoo · Sep 4, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By